Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 5Completed 5Withdrawn 1Terminated 1Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

blinatumomab 3Cytarabine 2Cyclophosphamide 2Azacitidine 2venetoclax 1sabatolimab 1ruxolitinib 1pulrodemstat besilate 1pembrolizumab 1peginterferon alfa-2a 1nilotinib 1fludarabine 1daratumumab 1Zoledronic Acid 1Vitamin D 1Methotrexate 1Imatinib Mesylate 1GNKG168 1Dasatinib 1Clofarabine 1Celecoxib 1Calcium 1CD3 Complex 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasm, Residual × fludarabine × Clear all
NCT05601830 2024-11-06

Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease

Institute of Hematology & Blood Diseases Hospital, China

Phase 1 Terminated
1 enrolled
Tumor-Agnostic

Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡